Danish State Growth Fund

Global Developments in Germany, Canada and Brazil Germany has approved a large phase 2b study on psilocybin for treatment-resistant depression. Dr. Gerhard Gründer, of the Central Institute of Mental Health Mannheim, will lead the study alongside the Department of Psychiatry and...